GET DAILY SIGNALSIntuitive Surgical (ISRG) Delivers Strong Q3 Growth but Shares Fall -10% on Narrowed Guidance
Key Takeaways
- Revenue rose 21.7% year over year to $3.05 billion, topping FactSet consensus of roughly $2.91 billion.
- Adjusted earnings per share (EPS) came in at $3.00, well above analyst estimates of about $2.64 to $2.65.
- GAAP (Generally Accepted Accounting Principles) net income fell to $522.8 million, or $1.49 per share, down from $704.4 million, or $1.95 per share, a year earlier, hurt by a litigation charge.
- Worldwide procedures grew about 15%, with da Vinci procedures up 14% and Ion procedures up 31%.
- Full-year 2026 da Vinci procedure growth guidance was narrowed to a 14% to 15% range.
- Shares slid roughly 10% in after-hours trading despite the earnings beat.
Why These Quarterly Results Matter
Intuitive Surgical remains the clear leader in robotic-assisted surgery, and its quarterly updates serve as a useful gauge of hospital spending and demand for less invasive procedures. The company has consistently topped expectations thanks to rising procedure volumes and an expanding base of da Vinci systems. This third-quarter report was particularly telling because it showed whether procedure growth could hold up while also highlighting the earnings impact of a sizable litigation charge. I was focused on both the revenue momentum and how the updated guidance would shape the rest of the year.
What the Numbers Showed
Intuitive Surgical posted third-quarter 2026 revenue of $3.05 billion, a 21.7% increase from $2.51 billion a year earlier and ahead of the FactSet consensus near $2.91 billion. Adjusted EPS reached $3.00, comfortably above the $2.64 to $2.65 range analysts had projected.
GAAP net income dropped to $522.8 million, or $1.49 per diluted share, from $704.4 million, or $1.95 per diluted share, in the prior-year quarter. The decline stemmed from a pretax litigation charge that trimmed earnings by roughly 99 cents per share after tax.
Worldwide procedures rose about 15%, with da Vinci procedures advancing 14% and Ion procedures climbing 31%. The company placed 546 da Vinci systems compared with 427 a year ago, including 315 da Vinci 5 units versus 240 in the same period last year. Instruments and accessories revenue grew 18% to $1.80 billion, while systems revenue increased to $769 million from $590 million. The company finished the quarter with roughly $6.80 billion in cash, cash equivalents, and investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Even with the earnings beat, Intuitive Surgical shares declined about 10% in after-hours trading to around $391. The move appeared tied mainly to the narrowed full-year procedure growth outlook of 14% to 15%, down from the previous 13.5% to 15.5% range. Although the midpoint held steady, investors seemed disappointed by the tighter upper bound. The litigation charge also pressured GAAP results, though adjusted figures stayed solid. From what I see, the reaction reflected elevated expectations already priced into the stock rather than any weakening in the underlying business.
What to Watch Going Forward
Procedure volume trends will stay central because they drive the bulk of recurring revenue. The tightened 14% to 15% guidance for worldwide da Vinci procedures in 2026 offers a clear benchmark for the fourth quarter.
System placements and adoption of the da Vinci 5 platform deserve attention as well. Healthy placements point to customer interest in upgrades, though capital spending can vary quarter to quarter. The continued expansion of the Ion platform for lung biopsies remains a longer-term positive as reimbursement and geographic reach improve.
Margin trends, pricing on high-volume procedures, and international growth—especially in Europe and Asia—will also matter, even with ongoing challenges in China. I’m watching this closely to see whether procedure growth can pick up again and whether the litigation issue creates any additional effects.
Using Tickeron’s AI Tools for Deeper Analysis
When reviewing results like these, I often turn to Tickeron’s AI Screener to quickly compare ISRG against peers on fundamentals, technical patterns, and AI-driven signals. It helps surface relevant watchlists and spot how the stock stacks up in the broader medical-device space without spending hours on manual screening. The tool has become a regular part of my process for staying on top of names in this sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ISRG sees MACD Histogram just turned negative
ISRG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 31 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 13 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 34%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 62 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 265 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.805) is normal, around the industry mean (4.964). P/E Ratio (51.222) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement